Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.

Journal of managed care & specialty pharmacy·2026

Same author

AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-making.

Journal of managed care & specialty pharmacy·2025

Same author

Expanding Access to Photobiomodulation Treatment for Paediatric Oncology Patients in Glasgow.

International journal of paediatric dentistry·2025

Same author

Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.

Journal of managed care & specialty pharmacy·2025

Same author

Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.

Journal of managed care & specialty pharmacy·2025

Same author

Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.

Journal of managed care & specialty pharmacy·2024

Same journal

Should eligibility for medication therapy management be based on drug adherence?

Journal of managed care pharmacy : JMCP·2014

Same journal

Medication adherence in a sample of elderly suffering from hypertension: evaluating the influence of illness perceptions, treatment beliefs, and illness burden.

Journal of managed care pharmacy : JMCP·2014

Same journal

Pharmacists' role in the care of patients with heart failure: review and future evolution.

Journal of managed care pharmacy : JMCP·2014

Same journal

PCMHs, ACOs, and medication management: lessons learned from early research partnerships.

Journal of managed care pharmacy : JMCP·2014

Same journal

Adherence to national recommendations for safe methotrexate dispensing in community pharmacies.

Journal of managed care pharmacy : JMCP·2014

Same journal

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.

Journal of managed care pharmacy : JMCP·2014

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Dalfampridine prior authorization program: a cohort study.

Patrick P Gleason¹, Jill Phillips, Beckie A Fenrick

¹Prime Therapeutics LLC, Eagan, MN 55121, USA. pgleason@primetherapeutics.com

Journal of Managed Care Pharmacy : JMCP

|February 7, 2013

Summary

This summary is machine-generated.

A prior authorization (PA) program for dalfampridine (Ampyra) improved safety and reduced costs in multiple sclerosis (MS) patients. The PA program effectively identified appropriate users for initial therapy, demonstrating its value in managing this MS medication.

Related Experiment Videos

Last Updated: May 14, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Area of Science:

Pharmacoeconomics
Health Services Research
Neurology

Background:

Dalfampridine (Ampyra) improves walking in multiple sclerosis (MS) patients but carries seizure risks, especially with renal impairment.
A prior authorization (PA) program was implemented to ensure safe and appropriate dalfampridine use, aligning with FDA labeling.

Purpose of the Study:

To evaluate the impact of a 2-phase dalfampridine PA program on review decisions, utilization, and pharmacy expenditures.
To compare outcomes between MS patients exposed to the PA program and those without PA exposure.

Main Methods:

Retrospective analysis of administrative pharmacy claims data from a large commercial health plan.
Comparison of dalfampridine utilization and costs between a PA-implemented group and a control group over a defined enrollment period.

Main Results:

The PA program resulted in significantly fewer dalfampridine claims per member (2.1 fewer, P < 0.001).
An estimated cost avoidance of $143,010 was achieved, equating to $0.03 per member per month.
The PA program effectively selected appropriate initial therapy users, though overall trend differences in utilization over time were not significant between groups.

Conclusions:

A dalfampridine PA program can enhance patient safety and reduce medication costs.
PA programs are effective in identifying appropriate candidates for initiating dalfampridine therapy.
Integrating care management could further optimize dalfampridine use through adherence monitoring and response tracking.